The current status of immunobased therapies for metastatic renal-cell carcinoma

Niranjan J Sathianathen, Suprita Krishna, J Kyle Anderson, Christopher J Weight, Shilpa Gupta, Badrinath R Konety, Thomas S Griffith

Research output: Contribution to journalArticlepeer-review


The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.
Original languageEnglish (US)
Pages (from-to)83-93
Number of pages11
JournalImmunoTargets and Therapy
VolumeVolume 6
StatePublished - 2017


  • cryosurgery
  • immunocheckpoints
  • immunotherapy
  • kidney neoplasm
  • targeted therapy
  • vaccines

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'The current status of immunobased therapies for metastatic renal-cell carcinoma'. Together they form a unique fingerprint.

Cite this